Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from&amp;nbsp;latanoprost

Maruyama, Yuko; Ikeda, Yoko; Mori, Kazuhiko; Ueno, Masaki; Yoshikawa, Haruna; Kinoshita, Shigeru

doi:10.2147/opth.s87613

Cited by 6 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, no significant differences were found between Lat and Taf in regard to IOP reduction effects, conjunctival hyperemia score, and corneal epitheliopathy score, as well as eyelash change and eyelid and iris pigmentation. It has been reported that conjunctival hyperemia becomes stronger when switching from Lat to travoprost or bimatoprost, 14 , 15 and the same tendency was found to be true in this present study when switching from Lat to Taf. Although there were no statistically significant differences, elongation of eyelash length was more frequently found in Lat, whereas increased eyelash amount was more frequently found in Taf.…”

Section: Discussionsupporting

confidence: 88%

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Ikeda¹,

Mori²,

Tada³

et al. 2016

OPTH

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate and compare the intraocular pressure (IOP) reduction efficacy and safety between the ophthalmic solutions 0.005% latanoprost (Lat) and 0.0015% tafluprost (Taf) in Japanese patients with normal-tension glaucoma (NTG).MethodsIn this randomized nonmasked study, we prospectively enrolled 30 Japanese NTG patients who had used Lat monotherapy for more than 4 weeks, and randomly divided them into the following two groups: 1) Lat-to-Taf group (LT group) and 2) Taf-to-Lat group (TL group). At the beginning of the study, both groups were switched from initial Lat to Lat or Taf for 12 weeks, and then switched over to the other drug (crossover) for 12 additional weeks. At 0, 4, 12, 16, and 24 weeks, we evaluated each patient’s IOP, conjunctival injection, and corneal epitheliopathy score, and at 0, 12, and 24 weeks, we evaluated their eyelash changes and pigmentation of the eyelids and irises.ResultsThe mean IOP of the LT group (15 eyes) was 10.5, 10.6, and 11.1 mmHg, at 0, 12, and 24 weeks, respectively, whereas that of the TL group (15 eyes) was 11.7, 11.1, and 10.5 mmHg at 0, 12, and 24 weeks, respectively. No significant differences were found between the two groups and in the intragroup comparisons. Moreover, no significant differences were found between Lat and Taf in regard to the conjunctival injection score and corneal epitheliopathy score. Eyelash changes and eyelid and iris pigmentation were similar in both groups.ConclusionThe findings of this study show that Lat and Taf have equivalent efficacy and safety in Japanese patients with NTG.

show abstract

Section: Discussionsupporting

confidence: 88%

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Ikeda¹,

Mori²,

Tada³

et al. 2016

OPTH

Self Cite

View full text Add to dashboard Cite

show abstract

“…This observation was consistent with previous studies [ 11 , 12 , 24 - 26 ] showing that bimatoprost has a greater potential for IOP reduction than latanoprost. Sato et al reported that patients with NTG whose response to latanoprost was insufficient showed a further significant IOP reduction by switching from latanoprost to bimatoprost [ 27 ].…”

Section: Discussionsupporting

confidence: 93%

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost

Imasawa

Tanabe

Kashiwagi

et al. 2016

TOOPHTJ

View full text Add to dashboard Cite

Purpose: To prospectively assess the efficacy and safety of switching to bimatoprost monotherapy or brinzolamide and latanoprost combination therapy in patients who had been receiving latanoprost monotherapy.Methods: A prospective, open-label study was conducted. Patients with primary open-angle glaucoma or ocular hypertension who had been receiving latanoprost monotherapy for three months or more were enrolled. Bimatoprost was substituted for latanoprost in one eye (BIM group), and brinzolamide was added to the latanoprost in the other eye (BRZ group) simultaneously. The patients underwent examinations at 6 weeks (visit 1) and 12 weeks (visit 2) after changing therapies. Subsequently, the treatments were returned to latanoprost monotherapy. The patients underwent another examination 6 weeks (visit 3) after the return to latanoprost. The parameters examined were intraocular pressure (IOP), conjunctival hyperemia, and corneal epithelial damage. Results: Twenty-six patients (13 men and 13 women) completed the protocol. Both groups showed a significant IOP reduction at visits 1 and 2 compared with the baseline, with a similar magnitude (BIM group: P = 0.016 at visit 1, P = 0.025 at visit 2, BRZ group: P = 0.0006 at visit 1, P = 0.028 at visit 2). The IOPs at the baseline and on visit 3 were similar in both groups (P = 0.7). The two groups showed no changes in either conjunctival hyperemia or corneal epithelial damage compared with the baseline. Conclusion: Bimatoprost monotherapy and brinzolamide adjunctive to latanoprost similarly reduced the IOP, with no additive adverse effects, compared with latanoprost monotherapy.

show abstract

“…In common with the paper by Maruyama et al that compared BTFC with latanoprost plus timolol FC, 21 we noted a slightly higher proportion of patients showing conjunctival hyperemia with BTFC (18.6% vs 10.3%). A slightly higher proportion of patients showed superficial keratitis with DTFC (9.3% vs 5.1%).…”

Section: Discussionsupporting

confidence: 90%

“…14,15 These findings have been corroborated by two recent meta-analyses reporting that prostaglandin plus timolol FCs lead to a significantly lower incidence of ocular hyperemia than monotherapy with their respective prostaglandins. 21,28 In our work, the overall proportion of patients with treatment related adverse event was 19.6% and 23.7% with DTFC and BTFC respectively.…”

Section: Discussionmentioning

confidence: 47%

“…19,20 However, a recent prospective study compared the efficacy of BTFC with latanoprost plus timolol FC in patients switched from latanoprost monotherapy and this study showed no significant differences in mean IOP between the two fixed combinations. 21 In addition, Schnober Figure 1. Mean intraocular pressure ± 95% CI at each individual time point and for the diurnal intraocular pressure for baseline, DTFC, and BTFC treatment groups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Bimatoprost Plus Timolol Fixed Combination in Open Angle Glaucoma Patients Previously Treated with Dorzolamide Plus Timolol Fixed Combination

Sacchi

Specchia

Williams

et al. 2016

Current Eye Research

View full text Add to dashboard Cite

show abstract

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost

Cited by 6 publications

References 39 publications

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost

Efficacy of Bimatoprost Plus Timolol Fixed Combination in Open Angle Glaucoma Patients Previously Treated with Dorzolamide Plus Timolol Fixed Combination

Contact Info

Product

Resources

About